CHOSA Oncology AB announces approved re-listing memorandum
CHOSA Oncology AB (publ) ("CHOSA" or the "Company"), formerly RhoVac, announces that Spotlight Stock Market ("Spotlight") today approved the relisting memorandum that the Company was required to draw up in connection with the Company's reverse acquisition of the Danish CHOSA ApS.The approval of the re-listing memorandum also confirms that Spotlight considers CHOSA to meet all current listing requirements. As a result, trading in the Company's shares will be re-listed on the ordinary list.CHOSA, which through the reverse acquisition of CHOSA ApS now owns the licensing rights to the drug